Neil Berkley serves as Chief Financial Officer and Chief Business Officer at Alector Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative diseases by harnessing the immune system. In his dual role, Berkley oversees all financial operations, including strategic planning, investor relations, capital raising, and accounting. As Chief Business Officer, he leads business development efforts, forging key partnerships and alliances to advance Alector's pipeline of innovative immuno-neurology programs targeting Alzheimer's disease and other brain disorders. Prior to joining Alector in 2022, Berkley built an illustrious career in biotech finance. He served as CFO at Five Prime Therapeutics from 2018 to 2021, guiding the company through pivotal financings and its $1.9 billion acquisition by Amgen. Earlier, as CFO of Relypsa, Inc. from 2014 to 2016, he orchestrated the firm's $1.3 billion sale to Galenica Group (now Vifor Pharma), following a successful IPO and multiple venture rounds. His tenure at these companies exemplifies his expertise in scaling operations amid rapid growth and M&A milestones. Berkley's professional journey began at Genentech, a Roche company, where he spent 13 years in progressively senior finance and operations roles, including Director of Finance for U.S. Commercial Operations. His achievements include raising over $1 billion in equity and debt financings across his career, optimizing financial infrastructures, and navigating complex regulatory landscapes. At Alector, Berkley continues to drive financial discipline and strategic growth, positioning the company for long-term success in transforming neurodegeneration treatment.